Defence Therapeutics Inc.
DTCFF · OTC
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -2.05 | -0.24 | 0.19 | 11.17 |
| FCF Yield | -2.83% | -2.62% | 0.35% | -1.27% |
| EV / EBITDA | -82.11 | -39.37 | -56.00 | -36.61 |
| Quality | ||||
| ROIC | -87.66% | 0.00% | 0.00% | 61.23% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 2.10 | 0.83 | -0.14 | 0.39 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -198.62% | -864.67% | 116.96% | 55.38% |
| Safety | ||||
| Net Debt / EBITDA | 0.81 | -1.70 | -3.56 | -1.47 |
| Interest Coverage | -12.33 | 0.00 | 0.00 | -7.55 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |